Loading stock…

Xeris Biopharma Holdings, Inc. (XERS) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Xeris Biopharma Holdings, Inc.

XERSMarket cap $1.84BPrice $10.1

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops ready-to-use injectable and biologic therapies for endocrine and neurological disorders, replacing painful powder-mixing steps patients hate. Its glucagon rescue pen treats severe low blood sugar in seconds, no reconstitution needed, potentially saving lives when minutes truly matter.

In Bastion Portfolios?

52W Return+9%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+38%10

Revenue Forecast

Rev CAGR (1y)+33%9

Rev CAGR (3y)+24%9

Rev CAGR (5y)+20%9

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+20%5

EPS Growth Y+3+70%10

Quality

Margins

EBIT Margin11%5

Net Income Margin-5%1

Free Cash Flow Margin17%7

Debt

Net Debt/EBITDA3.03

Efficiency

ROEna–

ROA-5%1

Earnings Stability22

GEAR+WEAK31

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)591

P/E Ratio (Forward 3y)213

P/BVna–

EV Multiples

EV/EBITDA Fwd341

EV/EBIT Fwd551

Yield

Free Cash Flow Yield3.0%5

Dividend Yieldna–

Momentum

Short term

1 month return+19%10

3 month return+17%9

YTD return+29%8

Mid term

Price vs 52wHigh89%8

1 year return+23%7

Long term

3 year return+478%10

5 year return+384%10

Risk Shield

Price Risk

Beta1.14

Volatility55%3

Free Cash Flow

Free Cash Flow Margin17%7

Free Cash Flow Yield3.0%5

Quality

ROCE16%8

Earnings Stability22

Net Debt/EBITDA3.03

02Growth

Is it actually growing, and how fast?

XERSXeris Biopharma Holdings

Revenue FY25$292M

GROWTH RATING↗

VERY STRONG88 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+38%10

Revenue, next 1Y+33%9

Revenue, next 3Y, CAGR+24%9

Revenue, next 5Y, CAGR+20%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+70%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 88% of companies worldwide.

Revenue grew 38%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 24%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 20%/yr over five years.9/10

WATCH

Revenue grew 38%/yr over the last 3 years; forecasts see it cooling to 24%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG96 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+19%10

3-month return+17%9

YTD return+29%8

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+23%7

3-year return+478%10

5-year return+384%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +478% over three years and +384% over five, ahead of 90% of the market.

It's up 23% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+19%), over three months (+17%) and so far this year (+29%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Xeris Biopharma Holdings, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

XERSXeris Biopharma Holdings

Revenue FY25$292M

GROWTH RATING↗

VERY STRONG88 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+38%10

Revenue, next 1Y+33%9

Revenue, next 3Y, CAGR+24%9

Revenue, next 5Y, CAGR+20%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+70%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 88% of companies worldwide.

Revenue grew 38%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 24%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 20%/yr over five years.9/10

WATCH

Revenue grew 38%/yr over the last 3 years; forecasts see it cooling to 24%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG96 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+19%10

3-month return+17%9

YTD return+29%8

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+23%7

3-year return+478%10

5-year return+384%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +478% over three years and +384% over five, ahead of 90% of the market.

It's up 23% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+19%), over three months (+17%) and so far this year (+29%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Xeris Biopharma Holdings, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community